MEMORANDUM

To:	Subcommittee on Health Members and Staff
From:	Committee on Energy and Commerce Majority Staff
Re:	Health Subcommittee Hearing on November 29, 2023

The Subcommittee on Health will hold a hearing on Wednesday, November 29, 2023, at 10:30 a.m. (ET) in 2322 Rayburn House Office Building. The hearing is entitled "Understanding How AI is Changing Health Care."

I. Witnesses

- **Dr. Michael Schlosser, M.D., MBA,** Senior Vice President of Care Transformation and Innovation, HCA Healthcare;
- **Dr. Benjamin Nguyen**, Senior Product Manager, Transcarent;
- **Mr. Peter Shen**, Head of Digital Health – North America, Siemens Healthineers;
- **Dr. Christopher Longhurst, M.D.,** Chief Medical Officer, Chief Digital Officer, and Association Dean, UC San Diego Health; and,
- **Dr. David Newman-Toker, M.D., Ph.D.,** Director, Division of Neuro-Visual and Vestibular Disorders, Department of Neurology, Professor of Neurology, Johns Hopkins University School of Medicine.

II. Background

Artificial Intelligence (AI) offers potential opportunities to improve the efficiency and overall effectiveness of the American health care system. The practical uses of AI have grown and are expected to continue increasing dramatically in the coming years.

AI is already a part of the current health care system. For example, AI is used to reduce the paperwork burden on physicians and hospitals, allowing them to dedicate less provider resources toward administrative functions and more toward patient care. Additionally, researchers, including from the National Cancer Institute, are actively exploring the potential for AI to improve the diagnosis of diseases.[1]

AI also has implications on medical innovation. According to the U.S. Food and Drug Administration (FDA) more than 100 drug and biologic applications submitted in 2021 included AI and machine learning (ML) components.[2] Earlier this year, the FDA published two discussion papers on the use of AI and ML in drug development and manufacturing. The use of AI is not limited to drugs, however. In October of 2023, the FDA added 171 medical devices to its list of Artificial Intelligence and Machine Learning-Enabled Medical Devices.

---

[1] Artificial Intelligence - NCI (cancer.gov)
[2] FDA Releases Two Discussion Papers to Spur Conversation about Artificial Intelligence and Machine Learning in Drug Development and Manufacturing | FDA

It is reasonable to assume that the use of AI and ML increasingly will be imbedded into different aspects of health care. Congress must understand how the technology is currently being used, and the potential applications that future innovations may have. Congress must also understand how the technology interacts with existing regulations and evaluate those paradigms to ensure AI does not cause harm. This hearing will explore how AI is currently being used in medical devices, and in hospitals and what Congress should consider as AI in health care evolves.

III. Staff Contacts

If you have questions regarding this hearing, please contact Caitlin Wilson or Jolie Brochin of the Committee staff at 202-225-3641.